ACE-031
Also known as: ACE-031
ACE-031 is a soluble decoy receptor (ActRIIB-Fc fusion) studied as a myostatin inhibitor to increase muscle mass and strength.
Last updated
Mechanism of Action
ACE-031 is a fusion protein combining the extracellular domain of activin receptor type IIB (ActRIIB) with an IgG1 Fc region. It acts as a ligand trap, binding circulating myostatin (GDF-8), activin A, and other TGF-beta superfamily ligands before they can engage ActRIIB on muscle cells. By preventing receptor activation, it blocks downstream SMAD2/3 signaling that normally restrains muscle growth, leading to muscle hypertrophy and increased bone density in animal and early clinical models.
- Half-life
- Approximately 10 to 15 days (Fc-fusion, long-acting)
- Administration Routes
- subcutaneous
- Research Status
- Preclinical
Reported Benefits
- Inhibits myostatin to promote muscle hypertrophy
- Studied for increased lean muscle mass
- May improve muscle strength
- Investigated for increased bone mineral density
- Explored in muscular dystrophy research
Potential Side Effects
- Reported dilated blood vessels (telangiectasia) and nosebleeds in trials
- Gum bleeding reported in clinical study participants
- Headache
- Injection-site reactions
- Unknown long-term safety; a clinical trial was halted over safety signals
Common Dosing
For research use only; clinical studies explored single and repeat subcutaneous doses in the range of roughly 1 to 3 mg/kg every few weeks. This is not personal medical guidance.
The dosing information above is aggregated from research literature and anecdotal community reports for educational purposes only. It is not a recommendation, prescription, or medical advice. Peptides are sold as research chemicals only and are not intended for human use.
Contraindications
- Not for human or clinical use outside trials
- History of bleeding disorders or vascular abnormalities
- Pregnancy or breastfeeding
Follistatin 344
Follistatin 344 is the full-length precursor isoform of follistatin studied for blocking myostatin and activin to drive muscle growth and tissue repair.
IGF-1 LR3
IGF-1 LR3 (Long R3 IGF-1) is an engineered, long-acting analog of insulin-like growth factor 1 studied for sustained anabolic and tissue-growth signaling. Its modifications give it a far longer half-life than native IGF-1.
- View
Myostatin inhibitor ACE-031 treatment of ambulatory boys with Duchenne muscular dystrophy: Results of a randomized, placebo-controlled clinical trial
2017
- View
A single ascending-dose study of muscle regulator ACE-031 in healthy volunteers
2013
- View
ACE-031, a soluble activin type IIB receptor, increases muscle mass and strength in the common marmoset (Callithrix jacchus)
2026
- View
Gel Electrophoretic Detection of Black Market ACE-031
2025